Log in
Nonsteroidal anti-inflammatory drug (NSAID)

Meloxicam

Meloxicam is a preferentially selective COX-2 inhibitor NSAID used primarily for chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis. Unlike traditional non-selective NSAIDs, meloxicam demonstrates greater selectivity for COX-2 over COX-1, potentially reducing gastrointestinal toxicity while maintaining anti-inflammatory efficacy. The most testable fact is that meloxicam carries the same cardiovascular and renal risks as other NSAIDs despite its COX-2 selectivity.

Practice questionsHigh-yield facts
Drug classPreferentially selective COX-2 inhibitor NSAID
MechanismInhibits COX-2 more than COX-1, reducing prostaglandin synthesis
Main usesOsteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis
Key adverse effectIncreased cardiovascular thrombotic events, GI bleeding
7 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Meloxicam is a preferentially selective cyclooxygenase-2 (COX-2) inhibitor within the enolic acid class of NSAIDs. It works by inhibiting the COX-2 enzyme responsible for the synthesis of pro-inflammatory prostaglandins, particularly prostaglandin E2 (PGE2), at sites of inflammation. While meloxicam shows preferential selectivity for COX-2 over COX-1 (approximately 10:1 ratio at therapeutic doses), it is not completely COX-2 specific like celecoxib.

COX-1 is constitutively expressed in most tissues and is responsible for producing prostaglandins that maintain gastric mucosal integrity, platelet function, and renal blood flow. COX-2 is primarily induced at sites of inflammation by cytokines and inflammatory mediators. By preferentially inhibiting COX-2, meloxicam reduces inflammation, pain, and fever while theoretically causing less gastrointestinal toxicity compared to non-selective NSAIDs. However, at higher doses or in certain patients, meloxicam loses its selectivity and inhibits both COX isoforms.

The anti-inflammatory and analgesic effects result from decreased prostaglandin synthesis in peripheral tissues and the central nervous system. Meloxicam does not modify the underlying disease process in arthritis but provides symptomatic relief by reducing inflammation and pain.

High-yield for exams
  • Meloxicam is a preferentially selective COX-2 inhibitor, not completely COX-2 specific like celecoxib.
  • Black Box Warnings: increased risk of cardiovascular thrombotic events (MI, stroke) and serious GI bleeding, ulceration, perforation.
  • Contraindicated in perioperative CABG surgery and third trimester of pregnancy (premature ductus arteriosus closure).
  • Long half-life (15-20 hours) allows once-daily dosing for chronic inflammatory conditions.
  • Reduces antihypertensive efficacy of ACE inhibitors, ARBs, and diuretics; increases risk of acute kidney injury when combined.
  • Increases lithium and methotrexate levels by reducing renal clearance; monitor drug levels closely.
  • Cross-reacts in aspirin-sensitive asthmatics despite COX-2 selectivity; can precipitate bronchospasm.
  • Minimal antiplatelet effect compared to non-selective NSAIDs; does not provide cardiovascular protection.

Indications

Meloxicam is FDA-approved for the following indications:

  • Osteoarthritis: symptomatic treatment of pain and inflammation
  • Rheumatoid arthritis: reduction of signs and symptoms in adults
  • Juvenile idiopathic arthritis (pauciarticular or polyarticular): in patients 2 years of age and older

Off-label uses

Meloxicam is commonly used off-label for:

  • Ankylosing spondylitis
  • Acute pain and dysmenorrhea
  • Gout flares (acute management)
  • Postoperative pain

Meloxicam is intended for chronic use in inflammatory arthritis rather than acute pain management, where shorter-acting NSAIDs may be more appropriate. It should be prescribed at the lowest effective dose for the shortest duration necessary to minimize adverse effects.

Pharmacokinetics

Meloxicam demonstrates predictable pharmacokinetic properties that support once-daily dosing:

Absorption: Well absorbed after oral administration with bioavailability of approximately 89%. Peak plasma concentrations occur 4-5 hours after dosing. Food does not significantly alter absorption.

Distribution: Highly protein-bound (>99%, primarily to albumin). Volume of distribution is approximately 10 L. Meloxicam penetrates into synovial fluid, reaching concentrations approximately 50% of plasma levels.

Metabolism: Extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2C9 and to a lesser extent CYP3A4. Four pharmacologically inactive metabolites are formed.

Elimination: Eliminated equally in urine and feces as metabolites. Less than 5% is excreted unchanged in urine. The elimination half-life is approximately 15-20 hours, allowing for once-daily dosing. Clearance is reduced in elderly patients, patients with hepatic impairment, and those with severe renal impairment.

Special populations: Dose adjustment is not routinely required in elderly patients or those with mild-to-moderate renal or hepatic impairment, but lower starting doses should be considered. Meloxicam is not recommended in severe renal impairment or severe hepatic disease.

Adverse effects

Meloxicam shares the adverse effect profile of NSAIDs, though with potentially reduced gastrointestinal toxicity due to COX-2 selectivity:

Gastrointestinal

  • Dyspepsia, abdominal pain, nausea, diarrhea (most common)
  • Peptic ulcer disease, GI bleeding, and perforation (Black Box Warning)
  • Lower risk than non-selective NSAIDs but still significant, especially in elderly or those with prior GI events

Cardiovascular

  • Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke (Black Box Warning)
  • Hypertension (new onset or exacerbation)
  • Edema and fluid retention
  • Heart failure exacerbation

Renal

  • Acute kidney injury and acute interstitial nephritis
  • Hyperkalemia
  • Sodium and water retention
  • Papillary necrosis with chronic use
  • Reduced renal function in patients dependent on prostaglandins for renal perfusion

Hepatic

  • Elevated liver enzymes (transaminases)
  • Rare cases of severe hepatotoxicity, including jaundice and fatal hepatitis

Hematologic

  • Anemia (due to GI blood loss or bone marrow suppression)
  • Thrombocytopenia (rare)
  • Less antiplatelet effect than aspirin or non-selective NSAIDs

Dermatologic

  • Rash, pruritus
  • Serious skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis (rare but serious)

Hypersensitivity

  • Anaphylaxis and angioedema (rare)
  • Bronchospasm in aspirin-sensitive asthmatics (cross-reactivity)

Other

  • Headache, dizziness
  • Tinnitus (less common than with aspirin)

Contraindications and warnings

Absolute contraindications

  • Known hypersensitivity to meloxicam, aspirin, or other NSAIDs
  • History of asthma, urticaria, or allergic reactions after taking aspirin or NSAIDs (risk of severe bronchospasm)
  • Perioperative setting of coronary artery bypass graft (CABG) surgery (Black Box Warning)
  • Active peptic ulcer disease or recent GI bleeding
  • Severe hepatic impairment
  • Severe renal impairment (CrCl <15 mL/min) or end-stage renal disease
  • Third trimester of pregnancy (risk of premature closure of ductus arteriosus)

Black Box Warnings

Cardiovascular thrombotic events: NSAIDs increase the risk of serious cardiovascular thrombotic events, MI, and stroke, which can be fatal. Risk may increase with duration of use and in patients with cardiovascular disease or risk factors.

Gastrointestinal bleeding, ulceration, and perforation: NSAIDs cause serious GI adverse events including bleeding, ulceration, and perforation, which can be fatal. These events can occur at any time during use and without warning. Elderly patients and those with prior GI events are at greater risk.

Warnings and precautions

  • Hepatotoxicity: Monitor liver enzymes; discontinue if abnormal liver tests persist or worsen
  • Hypertension: Monitor blood pressure; NSAIDs can diminish antihypertensive drug effects
  • Heart failure: Use with caution; may cause fluid retention and edema
  • Renal toxicity: Monitor renal function in at-risk patients (elderly, volume-depleted, heart failure, renal impairment, cirrhosis)
  • Anaphylaxis: Can occur in patients without prior NSAID exposure
  • Pregnancy: Avoid use starting at 20 weeks gestation (oligohydramnios, fetal renal dysfunction risk); contraindicated in third trimester
  • Fertility: May impair female fertility (reversible upon discontinuation)
  • Asthma exacerbation: Use cautiously in patients with asthma; can precipitate bronchospasm
  • Serious skin reactions: Discontinue at first appearance of rash or hypersensitivity
  • Hematologic effects: Monitor hemoglobin/hematocrit in patients on long-term therapy

Drug interactions

Meloxicam participates in several clinically significant drug interactions:

Anticoagulants and antiplatelets

  • Warfarin, heparin, DOACs: Increased bleeding risk; monitor INR closely if warfarin is co-administered
  • Aspirin, clopidogrel, other antiplatelets: Synergistic increase in GI bleeding risk
  • NSAIDs may interfere with aspirin's cardioprotective antiplatelet effect

Antihypertensives

  • ACE inhibitors, ARBs: Reduced antihypertensive effect; increased risk of renal impairment, especially in volume-depleted or elderly patients
  • Diuretics: Reduced natriuretic and diuretic effects; increased risk of renal toxicity
  • Beta-blockers: Diminished antihypertensive effect

Other NSAIDs and corticosteroids

  • Concomitant use increases GI toxicity risk without added benefit; avoid combination
  • Aspirin increases meloxicam clearance and reduces its efficacy while increasing GI risk

Lithium

  • NSAIDs reduce renal lithium clearance, increasing lithium levels and toxicity risk; monitor lithium concentrations

Methotrexate

  • NSAIDs may increase methotrexate levels by reducing renal clearance; monitor for methotrexate toxicity, especially at high doses

SSRIs and SNRIs

  • Increased risk of GI bleeding when combined with NSAIDs; consider gastroprotection

CYP2C9 inhibitors

  • Fluconazole, amiodarone: May increase meloxicam levels by inhibiting metabolism; use lower meloxicam doses if necessary

Cyclosporine and tacrolimus

  • NSAIDs may potentiate nephrotoxicity of these immunosuppressants; monitor renal function closely

Cholestyramine

  • Accelerates meloxicam elimination; avoid concurrent use or separate administration

Clinical pearls

  • COX-2 selectivity is dose-dependent: At lower doses, meloxicam preferentially inhibits COX-2, but at higher doses or in certain individuals, it loses selectivity and inhibits both COX-1 and COX-2. This means GI-sparing benefits may diminish at higher doses.
  • Not completely COX-2 specific: Unlike celecoxib, meloxicam is classified as preferentially selective rather than highly selective for COX-2. It still carries cardiovascular and GI risks similar to traditional NSAIDs.
  • Once-daily dosing: The long half-life (15-20 hours) allows convenient once-daily administration, improving adherence in chronic conditions.
  • Cardiovascular risk applies to all NSAIDs: Despite COX-2 selectivity, meloxicam carries the same Black Box Warning for cardiovascular thrombotic events as non-selective NSAIDs. Prescribe the lowest effective dose for the shortest duration.
  • Consider gastroprotection: In high-risk patients (age >65, history of peptic ulcer, concurrent anticoagulants/steroids/SSRIs), co-prescribe a proton pump inhibitor to reduce GI bleeding risk.
  • Renal function monitoring: NSAIDs can precipitate acute kidney injury, especially in elderly patients, those with pre-existing renal disease, heart failure, cirrhosis, or volume depletion. Check baseline and periodic renal function.
  • Pregnancy timing matters: Avoid NSAIDs after 20 weeks gestation due to oligohydramnios and premature ductus arteriosus closure risk. Use is contraindicated in the third trimester.
  • Antiplatelet effect is minimal: Unlike aspirin and non-selective NSAIDs, meloxicam has minimal effect on platelet aggregation due to COX-2 selectivity. It does not provide cardioprotection.
  • Cross-reactivity in aspirin allergy: Patients with aspirin-exacerbated respiratory disease (AERD) or aspirin hypersensitivity may react to meloxicam due to COX inhibition, even though it is COX-2 preferential.
  • Hepatotoxicity monitoring: Check baseline liver enzymes and monitor periodically during long-term therapy. Discontinue if transaminases rise significantly or persistently.
  • Drug-drug interactions are common: Always review concomitant medications, especially anticoagulants, antihypertensives (ACE inhibitors, ARBs, diuretics), lithium, methotrexate, and SSRIs, as dose adjustments or additional monitoring may be needed.
  • Not first-line for acute pain: Due to its long half-life and time to peak effect, meloxicam is better suited for chronic inflammatory conditions than acute pain, where faster-acting NSAIDs (ibuprofen, naproxen) or acetaminophen may be preferable.

Practice questions

1. A 68-year-old woman with osteoarthritis of the knees presents for follow-up. She has been taking meloxicam 7.5 mg daily for 3 months with good pain control. Her medical history includes hypertension controlled on lisinopril and amlodipine. Today her blood pressure is 158/94 mmHg (previously 128/78 mmHg), and laboratory studies show creatinine increased from 1.0 to 1.6 mg/dL. Which of the following best explains her presentation?

Answer: C. Meloxicam inhibits COX enzymes, reducing prostaglandin synthesis in the kidneys. Prostaglandins maintain renal blood flow, especially in patients on ACE inhibitors like lisinopril. The combination reduces glomerular filtration, causing acute kidney injury and diminishing the antihypertensive effect of lisinopril, leading to elevated blood pressure. This is a classic drug-drug interaction between NSAIDs and ACE inhibitors. Lisinopril alone does not cause ATN, and there is no mention of diabetes. Amlodipine is a vasodilator, not a vasoconstrictor.

2. A 55-year-old man with rheumatoid arthritis presents to the emergency department with acute onset of black, tarry stools and lightheadedness. He has been taking meloxicam 15 mg daily for the past year. He also takes warfarin for atrial fibrillation. Vitals: BP 90/60 mmHg, HR 115/min. Hemoglobin is 7.2 g/dL (baseline 13.5 g/dL). Which mechanism best explains his complication?

Answer: C. This patient has upper GI bleeding (melena) from the combination of meloxicam-induced gastric mucosal injury and warfarin anticoagulation. NSAIDs inhibit COX-1 in the gastric mucosa, reducing protective prostaglandins and predisposing to ulcers and bleeding. Concurrent anticoagulation with warfarin markedly increases bleeding risk. This combination has an additive, not synergistic, effect on GI hemorrhage. Meloxicam does not affect vitamin K synthesis, and there is no evidence of portal hypertension or hemolysis.

3. A 72-year-old woman is started on meloxicam for osteoarthritis. Two weeks later, she presents with ankle swelling and shortness of breath. She has a history of heart failure with reduced ejection fraction (HFrEF), currently managed with carvedilol, furosemide, and lisinopril. Physical exam reveals bilateral pitting edema and bibasilar crackles. Which property of meloxicam is most responsible for her decompensation?

Answer: B. NSAIDs like meloxicam inhibit renal prostaglandin synthesis, reducing natriuresis and promoting sodium and water retention. This increases preload and can precipitate or worsen heart failure, especially in patients with pre-existing HFrEF. Additionally, NSAIDs reduce the efficacy of diuretics like furosemide. Meloxicam does not have direct cardiac depressant effects, does not inhibit carvedilol metabolism, and does not potentiate diuretics—it actually antagonizes them. While interstitial nephritis is possible, fluid retention is the primary mechanism of HF decompensation.

Frequently asked questions

How does meloxicam work?

Meloxicam works by preferentially inhibiting the cyclooxygenase-2 (COX-2) enzyme, which is responsible for producing pro-inflammatory prostaglandins at sites of inflammation. By selectively blocking COX-2 more than COX-1, meloxicam reduces pain, inflammation, and fever while theoretically causing less gastrointestinal damage than non-selective NSAIDs. However, at higher doses it loses selectivity and inhibits both COX isoforms, and it still carries significant cardiovascular and renal risks similar to other NSAIDs.

What are the side effects of meloxicam?

The most serious side effects of meloxicam include increased risk of heart attack, stroke, and cardiovascular thrombotic events, as well as gastrointestinal bleeding, ulcers, and perforation. Common side effects include stomach upset, nausea, diarrhea, headache, and dizziness. Meloxicam can also cause acute kidney injury, elevated blood pressure, fluid retention, liver enzyme elevations, and rarely serious skin reactions like Stevens-Johnson syndrome. Elderly patients and those with existing cardiovascular or kidney disease are at higher risk.

Is meloxicam a controlled substance?

No, meloxicam is not a controlled substance. It is a nonsteroidal anti-inflammatory drug (NSAID) available by prescription in most countries. Unlike opioid pain medications, meloxicam does not have abuse potential or risk of dependence, so it is not scheduled under controlled substance regulations. However, it does require a prescription due to its significant adverse effect profile, including cardiovascular and gastrointestinal risks.

Meloxicam vs ibuprofen — what is the difference?

Meloxicam is a preferentially selective COX-2 inhibitor with a long half-life allowing once-daily dosing, while ibuprofen is a non-selective NSAID that inhibits both COX-1 and COX-2 equally and requires multiple daily doses. Meloxicam may cause slightly less gastrointestinal toxicity due to its COX-2 selectivity, but both carry similar cardiovascular and renal risks. Ibuprofen has more antiplatelet effect and is better for acute pain, while meloxicam is typically reserved for chronic inflammatory conditions like osteoarthritis.

Can you take meloxicam during pregnancy?

Meloxicam should be avoided during pregnancy, especially after 20 weeks gestation and in the third trimester where it is contraindicated. NSAIDs can cause oligohydramnios, fetal renal dysfunction, and premature closure of the fetal ductus arteriosus, potentially leading to persistent pulmonary hypertension in the newborn. Use in early pregnancy may also increase miscarriage risk. If pain or inflammation management is needed during pregnancy, acetaminophen is generally considered safer, and any NSAID use should be discussed with a healthcare provider.

Conditions it is used for

OsteoarthritisRheumatoid arthritisJuvenile idiopathic arthritisAnkylosing spondylitisAcute goutMusculoskeletal painDysmenorrheaPostoperative pain
CelecoxibIbuprofenNaproxenDiclofenacIndomethacinPiroxicamKetorolacAspirin

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: M01AC06

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.